Methods of treating a complement associated eye condition by administering complement factor Bb antibodies
AssigneeAllergan, Inc.
InventorsYanbin Liang, Chen Li, Iris Lee, Victor M. Guzman
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies.
Claims20
A method for treating or reducing the occurrence of a complement-associated eye condition in a patient in need thereof, comprising administering to said patient an effective amount of a factor Bb antibody;
- thereby treating or reducing the occurrence of the complement-associated eye condition;
- wherein the antibody binds to Factor Bb with greater affinity than to Factor B;
- and inhibits complement dependent hemolysis;
- and wherein either:
- a. the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:8-11;
- and wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 12-15;
- or
- b. the light chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:24-27;
- and wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO:28-31.
Dependencies are inferred from the claim text.